FWDI

Forward Industries, Inc. - 10-Q Summary

Business Context and Reporting Period

Company: Forward Industries, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 2009 (Fiscal 2010 Q1)
Business Overview: The Company designs, markets, and distributes carry solutions (cases, bags, clips) primarily for handheld electronic devices, including medical monitoring kits (diabetic), cellular telephones, and bar code scanners. Principal customers are Original Equipment Manufacturers (OEMs).

Key Financial Metrics

Liquidity: The Company reported a current ratio of 12.23 and a quick ratio of 11.72. There is no short-term or long-term debt outstanding. A credit facility of up to $400,000 exists for a Swiss subsidiary but was expired as of the reporting date, with negotiations underway for renewal.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 22% ($1.18 million) year-over-year. This was driven primarily by a 24% decline in diabetic product sales ($1.0 million drop) and a 15% decline in "Other Products" ($0.2 million drop), largely due to reduced cell phone accessory demand.
• Improved Margins: Despite lower sales, gross margin improved from 17.8% to 22.4%. This was due to reduced quality assurance/sourcing costs, lower freight/duties, and lower inventory allowance charges compared to the prior year.
• Expense Reduction: Operating expenses decreased 17% ($0.22 million), primarily due to reduced selling personnel costs and travel expenses.
• Other Income: Other income dropped 92% to $7,212 from $88,304, driven by lower interest rates on cash balances.
• Net Loss: Net loss narrowed slightly by $17,438 due to expense reductions and margin improvements, offset by the loss of tax benefits and lower interest income.

Outlook, Risks, and Management Commentary

Management Commentary: Management attributes the revenue decline to the weak economy and reduced forecasts from major diabetic customers. However, they note signs that caution may be easing. The Company has cut operating expenses to near eight-year lows and does not anticipate further meaningful benefit from additional cuts. Future growth is expected to rely on winning new customers and potential acquisitions to diversify the business.

Risks and Contingencies:

• Customer Concentration: Sales are highly concentrated among a few large OEM customers, making results susceptible to significant variability.
• Product Concentration: Diabetic monitoring cases represented 75% of net sales.
• Guarantee Obligation: The Company has a contingent liability of approximately $315,000 (€224,000) related to a letter of credit for a Swiss subsidiary's logistics provider, which expired and is under negotiation for renewal.
• Deferred Tax Assets: The Company has established a full valuation allowance against its deferred tax assets ($652,000) due to uncertainty regarding future taxable income.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the top diabetic customers, particularly the major customer whose sales dropped by $1.1 million.
• Acquisition Strategy: Assess the progress of the Company's stated strategy to diversify via acquisition or investment.
• Credit Facility Renewal: Confirm the status of the renewal negotiations for the Swiss subsidiary's $400,000 credit facility and the associated $315,000 letter of credit guarantee.
• Inventory Levels: Monitor inventory levels and potential write-downs, as the Company holds finished goods based on OEM forecasts which can be volatile.
• Deferred Tax Realization: Watch for changes in the valuation allowance on deferred tax assets, which could impact future earnings if the Company determines realization is "more likely than not."